Real progress relies on producing a fatter pipeline of new drugs, which is GSK's main worry If your company's share price has gone roughly sideways for a decade, it's time to get radical. Emma Walmsley, the chief executive of GlaxoSmithKline, has given mixed messages about a breakup throughout her 18 months in the job, but now she's going for it. The consumer healthcare division will be combined into a joint venture with US rival Pfizer's smaller operation, paving the way for a demerger within t...
GSK's Pfizer deal is the first step towards fixing its share price | Nils Pratley
The Guardian - 19 Dec 2018 21:13
Real progress relies on producing a fatter pipeline of new drugs, which is GSK's main worry If your company's share price has gone roughly sideways for a decade, it's time to get radical. Emma Walmsley, the chief executive of GlaxoSmithKline, has given mixed messages about a breakup throughout her 18 months in the job, but now she's going for it. The consumer healthcare division will be combined into a joint venture with US rival Pfizer's smaller operation, paving the way for a demerger within t...
Share this Article
Recommended